Addressing the significant unmet need in cataract drug delivery

Efficient drug delivery remains a significant unmet need, with topical drops facing not only problems with compliance, but also with low rates of absorption into the eye

Addressing the significant unmet need in cataract drug delivery
Leigh Spielberg
Leigh Spielberg
Published: Friday, October 13, 2017
Professor Eric Donnenfeld   Professor Eric Donnenfeld, New York University, USA, delivered a presentation on the changing pharmaceutical treatment patterns in cataract surgery during a Main Symposium at the XXXV Congress of the ESCRS in Lisbon. “Efficient drug delivery remains a significant unmet need, with topical drops facing not only problems with compliance, but also with low rates of absorption into the eye,” said Prof Donnenfeld. He suggested that topical medications as we know them today will change greatly over the next several years, and he proceeded to outline the possibilities on the horizon. “The mucoadhesive DuraSite vehicle delivers sustained pharmacokinetics, maintaining therapeutic concentrations in the human conjunctiva up to six days after the last dose,” he said. Nanotechnologic mucus penetrating particles (MMPs) go a step further, diffusing through the mucus membranes and increasing penetration not only into the anterior segment, but also achieving high vitreous concentrations. MMPs are currently looking for FDA approval. Moving away from eye drops, Prof Donnenfeld described other modalities, such as punctal plug drug delivery. “Ocular Therapeutix has developed a bioabsorbable, intracanalicular hydrogel plug that can deliver dexamethasone for one month,” he said. “Evolute goes a step further, incorporating a punctal occlusion device to prevent loss of drug into the canaliculus.” Intracameral delivery has definitively proven its value in endophthalmitis prophylaxis. “The next step involves bioabsorbable, intracameral depots of, for example, dexamethasone, which would guarantee postoperative compliance, allow precise dosage, avoid topical toxicity and avoid systemic absorption,” concluded Prof Donnenfeld.          
Latest Articles
ESCRS Today 2025: Happy Anniversaries!

ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.

Read more...

ESCRS Today 2025: A Congress for Everyone

From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.

Read more...

ESCRS Today 2025: All Eyes on Innovation

Watching out for obstacles and opportunities

Read more...

Beyond the Numbers

Empowering patient participation fosters continuous innovation in cataract surgery.

Read more...

Thinking Beyond the Surgery Room

Practice management workshop focuses on financial operations and AI business applications.

Read more...

Aid Cuts Threaten Global Eye Care Progress

USAID closure leads retreat in development assistance.

Read more...

Supplement: ESCRS Clinical Trends Series: Presbyopia

Read more...

Debate: FS-LASIK or KLEx for Hyperopia?

FS-LASIK has more of a track record, but KLEx offers advantages.

Read more...

Four AI Applications Ready for Practice

Commercial offerings may save time, improve practice and research.

Read more...

Perioperative Medication Regimens for Cataract Surgery

Randomised controlled clinical trial results provide evidence-based guidance.

Read more...